A major adverse effect of glucocorticoid treatment is significant bone loss, which is most pronounced in the first 3 to 6 months of use.
Researchers evaluated the association between osteoporosis and vertebral fragility fractures with cardiovascular calcification in patients with chronic obstructive pulmonary disease.
Researchers evaluated the association between risk for atypical fracture and duration of bisphosphonate use in women with osteoporosis.
Researchers estimated risk for fracture among patients receiving denosumab with delayed subsequent doses vs those who received doses on time.
There is no clear benefit of bisphosphonates on bone marrow lesions.
In this systematic review, the study authors evaluated the current evidence on orthogeriatric care for older patients with hip fracture.
Researchers aimed to determine whether iron metabolism and serum hepcidin levels were linked to osteoporosis in patients with rheumatoid arthritis.
Researchers evaluated the effect of denosumab on bone mineral density loss in patients with glucocorticoid-induced osteoporosis.
Factors during gestation and infancy may impact bone health in young adulthood.
Given the limited data is available on bone health of patients with NMOSD-AQP4, researchers aimed to investigate their risk for fracture and bone loss.
Researchers evaluated the effects of follow-up therapy after denosumab discontinuation on bone resorption, bone mineral density, and clinical fracture risk.
Bone microarchitecture and strength are reduced in women living with HIV, and tenofovir treatment may contribute to bone deficits.
Want to read more?
Please login or register first to view this content.